Omalizumab substantially improves dermatology‐related quality of life in patients with chronic spontaneous urticaria
A.Y. Finlay(Cardiff University), Marcus Maurer(Humboldt-Universität zu Berlin), James L. Zazzali, Lisa A. Beck(University of Rochester Medicine), S Khalil(Novartis (Switzerland)), Evgeniya Antonova, M.M. Balp(Novartis (Switzerland)), Allen P. Kaplan(Medical University of South Carolina)
Cited by 50
Related Papers
Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use
|Clinical and Experimental Dermatology|1994|5.5k
Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report
|Journal of Allergy and Clinical Immunology|2010|2.3k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
Atopic dermatitis
|Nature Reviews Disease Primers|2018|1.5k